Clinical Trials Transparency

• The study of Jinyouli selected for presentation at ASCO

  The ASCO Annual Meeting 2022 focused on breast cancer studies. A study of Jinyouli was selected for presentation at this year's ASCO meeting.

• CSPC's study results of two innovative drugs selected for presentation at ESMO Congress

  CSPC Pharmaceutical Group will present the latest results from clinical trials of two innovative pipeline drugs at the European Society for Medical Oncology (ESMO) Congress 2022.

• New Study of Duomeisu on Breast Cancer

  New study of Duomeisu on breast cancer was published in Frontiers in Oncology (IF: 5.738; JCR Division: Oncology Zone 2).

• UPDATE ON THE CLINICAL STUDY PROGRESS OF SARS-CoV-2 mRNA VACCINE (SYS6006)

  SYS6006 (the “Product”) is the Group’s self-developed mRNA vaccine against the SARS-CoV-2 mutant strains, with 6 clinical studies initiated. An update on the study progress is provided below.

• Latest Clinical Study of Keaili in Gastric Cancer Treatment Was Released

  Recently, a study of Keaili was published in the Therapeutic Advances in Medical Oncology Journal.

• ESMO Focus | The Latest Research Findings of Doxorubicin Unveiled

  Recently, the annual meeting of the European Society for Medical Oncology (ESMO) is being held in Paris, France. One of the studies of Duomeisu was included in the conference.

• ESMO Focus | Duoenda's Research Findings Selected for Oral Session

  The annual meeting of the European Society for Medical Oncology (ESMO) was held in Paris, France. One of the studies about Duoenda was included in the conference.